Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Neonc Technologies, Inc.
Aulos Bioscience, Inc.
University of Michigan Rogel Cancer Center
M.D. Anderson Cancer Center
Bristol-Myers Squibb
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Suzhou Transcenta Therapeutics Co., Ltd.
Amgen
Bristol-Myers Squibb
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
BicycleTx Limited
Vedanta Biosciences, Inc.
TriSalus Life Sciences, Inc.
University of Pennsylvania
Bristol-Myers Squibb
Maastricht University Medical Center
7 Hills Pharma, LLC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Bolt Biotherapeutics, Inc.
TCR2 Therapeutics
Enterome
Incyte Corporation
Incyte Corporation
Herlev Hospital
ImmunityBio, Inc.
Sarcoma Oncology Research Center, LLC
Purple Biotech Ltd.
University Hospital Hradec Kralove
Fukushima Medical University
Fundacion Clinic per a la Recerca Biomédica
National Institutes of Health Clinical Center (CC)
University of California, San Diego
Kyowa Kirin Co., Ltd.
Suzhou Kintor Pharmaceutical Inc,
Novo Nordisk A/S
Gritstone bio, Inc.
Gritstone bio, Inc.
CNBG-Virogin Biotech (Shanghai) Ltd.
University of California, Davis
Oslo University Hospital
Nektar Therapeutics
Nektar Therapeutics
Brown University
University of Kansas Medical Center
Imperial College London
Incyte Corporation
Yonsei University